LANDSVIRKJUN
Landsvirkjun, The National Power Company of Iceland, and German investment company PCC SE have agreed to jointly explore the possibility of capturing and utilizing carbon emissions from PCC’s silicon metal plant in northeast Iceland. Carbon emissions will be utilized to produce green methanol that can for example replace fossil fuel in ships.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005136/en/
Green methanol will play a role in mitigating climate change
Methanol is not only a liquid chemical used in thousands of products of daily use, but green methanol is seen by many as a promising alternative energy carrier to fossil fuels and has the potential to play a key role in decarbonizing shipping vessels. The production of green methanol requires a renewable carbon source from PCC’s silicon metal plant in Iceland and renewable power from Landsvirkjun´s power stations. The process of methanol synthesis requires the input of pure carbon dioxide and hydrogen from water electrolysis, with the only by-product being oxygen and water. Turning carbon dioxide from waste into a valuable resource by utilizing and producing fuel for industries will help mitigate climate change and the transition to a circular economy.
Silicon metals used in innovative solutions for energy transition
PCC SE aims for their silicon metal plant at Húsavík to become carbon neutral by replacing fossil carbon reductants in their production with renewable alternatives. The plant at Bakki emits about 150,000 tonnes of carbon dioxide annually due to the nature of the chemical reaction that reduces quartzite (SiO2 ) with a carbon reductant to produce silicon metal. Catching and utilizing the emitted renewable carbon to produce green methanol would improve the carbon footprint of ships and industry utilizing such fuel and on top improve the carbon footprint of PCC’s silicon metal plant beyond carbon neutrality. Furthermore, the nature of silicon metals is such that without it, we would neither see the current stellar performance of solar power in the European Union, nor innovative solutions such as next generation battery anodes, which are key to higher capacities.
Peter Wenzel, CEO PCC SE:
“We are ready to take the next step at PCC BakkiSilicon; capture carbon emissions from our production and utilise for the energy transition. Our operations are already on track for carbon neutrality, but the production of green methanol, which can be used as maritime fuel, would certainly be a milestone.”
Hörður Arnarson, CEO Landsvirkjun:
“We at Landsvirkjun welcome the opportunity to collaborate on a green solution with a good customer. The energy transition is urgent, especially in the fleet. If we can use our renewable electricity to produce green methanol at PCC BakkiSilicon, we are one step closer to a green future.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005136/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom